Elan Makes Two Acquisitions for $380 Million

Elan Corp. acquired AOP Orphan Pharmaceuticals AG for 263.5 million euros ($340 million), expanding its business into medicines for rare diseases as it resists a takeover bid from Royalty Pharma.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.